STYRELSENS REDOGÖRELSE ENLIGT 14 KAP. 8 § AKTIEBOLAGSLAGEN THE BOARD OF DIRECTORS' REPORT IN ACCORDANCE WITH CHAPTER 14, SECTION 8 OF THE SWEDISH COMPANIES ACT

Med anledning av styrelsens förslag till beslut om emission av teckningsoptioner avger styrelsen härmed följande redogörelse enligt 14 kap 8 § aktiebolagslagen. De händelser av väsentlig betydelse för bolagets ställning som inträffat efter det att årsredovisningen för räkenskapsåret 2022 lämnades är beskrivna i bolagets pressmeddelanden och delårsrapporter, vilka finns tillgängliga på bolagets webbplats, www.expres2ionbio.com.

In connection with the board of directors' proposal for a resolution on the issuance of warrants, the board of directors hereby issues the following report in accordance with Chapter 14, Section 8 of the Swedish Companies Act. Events of significant importance to the company's financial position that have occurred after the annual report for the fiscal year 2022 was submitted are described in the company's press releases and interim reports, which are available on the company's website, www.expres2ionbio.com.

* * * * *

_______________________________

_______________________________

Martin Roland Jensen

Karin Garre

_______________________________

_______________________________

Jakob Knudsen

Sara Sande

The English text is a translation only and in case of any discrepancy the Swedish text shall control.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

ExpreS2ion Biotech Holding AB published this content on 24 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 October 2023 12:21:35 UTC.